EG20672A - Neuroprotective compounds - Google Patents

Neuroprotective compounds

Info

Publication number: EG20672A
Authority: EG; Egypt
Prior art keywords: pct; sec; date; neuroprotective compounds; pub
Prior art date: 1994-01-31

Application number

EG6795A

Other languages

English (en)

Inventor

Todd W Butler

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-31

Filing date

1995-01-28

Publication date

1999-11-30

1995-01-28 Application filed by Pfizer filed Critical Pfizer

1999-11-30 Application granted granted Critical

1999-11-30 Publication of EG20672A publication Critical patent/EG20672A/xx

Links

150000001875 compounds Chemical class 0.000 title 1
230000000324 neuroprotective effect Effects 0.000 title 1
JQQWDYJWDCIVKQ-QUCCMNQESA-N (3r,4s)-3-(4-benzyl-4-hydroxypiperidin-1-yl)-3,4-dihydro-2h-chromene-4,7-diol Chemical compound C1CN([C@H]2[C@H](C3=CC=C(O)C=C3OC2)O)CCC1(O)CC1=CC=CC=C1 JQQWDYJWDCIVKQ-QUCCMNQESA-N 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)
Saccharide Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EG6795A 1994-01-31 1995-01-28 Neuroprotective compounds EG20672A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18947994A	1994-01-31	1994-01-31

Publications (1)

Publication Number	Publication Date
EG20672A true EG20672A (en)	1999-11-30

Family

ID=22697514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG6795A EG20672A (en)	1994-01-31	1995-01-28	Neuroprotective compounds

Country Status (27)

Country	Link
US (1)	US5744483A (fr)
EP (1)	EP0741724B1 (fr)
JP (1)	JP2866743B2 (fr)
CN (1)	CN1048247C (fr)
AT (1)	ATE183184T1 (fr)
AU (1)	AU684568B2 (fr)
BR (2)	BR9408506A (fr)
CA (1)	CA2182101C (fr)
CO (1)	CO4230161A1 (fr)
CZ (1)	CZ286757B6 (fr)
DE (1)	DE69420053T2 (fr)
DK (1)	DK0741724T3 (fr)
EG (1)	EG20672A (fr)
ES (1)	ES2134361T3 (fr)
FI (1)	FI113769B (fr)
GR (1)	GR3031356T3 (fr)
HU (1)	HU221633B1 (fr)
IL (1)	IL112415A (fr)
MY (1)	MY111623A (fr)
NO (1)	NO309190B1 (fr)
NZ (1)	NZ275151A (fr)
PE (1)	PE43795A1 (fr)
PL (1)	PL179448B1 (fr)
RU (1)	RU2126404C1 (fr)
TW (1)	TW449591B (fr)
WO (1)	WO1995020587A1 (fr)
ZA (1)	ZA95692B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH11509839A (ja) *	1995-09-15	1999-08-31	ファイザー・インコーポレーテッド	薬剤活性を有するフェノール誘導体
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
UA73981C2 (en) *	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
US6407235B1 (en) *	2000-08-21	2002-06-18	Hoffmann-La Roche Inc.	Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1674087A1 (fr)	2000-10-02	2006-06-28	Pfizer Products Inc.	Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
ZA200108038B (en) *	2000-10-02	2003-04-01	Pfizer Prod Inc	Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
BR0211358A (pt) *	2001-07-26	2004-09-21	Merck Patent Gmbh	Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
RU2240113C1 (ru) *	2003-01-23	2004-11-20	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова	Способ экстренной медикаментозной помощи при острой травме спинного мозга
US7671072B2 (en) *	2003-11-26	2010-03-02	Pfizer Inc.	Aminopyrazole derivatives as GSK-3 inhibitors
WO2007051735A1 (fr)	2005-11-03	2007-05-10	F. Hoffmann-La Roche Ag	Dérivés d'indolylmaléimide en tant qu'inhibiteurs de protéine kinase
MX2008009414A (es) *	2006-01-20	2008-10-01	Schering Corp	Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa.
RU2418578C1 (ru) *	2009-12-08	2011-05-20	Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА
EP2522647B1 (fr) *	2011-05-10	2014-04-30	DSM IP Assets B.V.	Procédé de séparation d'isomères chiraux de composés de chromane et leurs dérivés et précurseurs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3294804A (en) *	1961-01-27	1966-12-27	Sterling Drug Inc	1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (fr) *	1966-09-27	1968-01-22
GB1495526A (en) *	1974-05-31	1977-12-21	Beecham Group Ltd	Chroman derivatives
US4016281A (en) *	1975-02-22	1977-04-05	Merck Patent Gesellschaft Mit Beschrankter Haftung	Tetralone and indanone compounds
US4082755A (en) *	1977-02-14	1978-04-04	Janssen Pharmaceutica N.V.	1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (fr) *	1978-07-03	1980-02-07	Sandoz Ag	Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4358456A (en) *	1980-05-03	1982-11-09	John Wyeth & Brother Limited	Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) *	1980-12-04	1982-07-08	C.H. Boehringer Sohn, 6507 Ingelheim	Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
GB2107706A (en) *	1981-09-25	1983-05-05	Beecham Group Plc	Benzopyrans
EP0093534A1 (fr) *	1982-04-28	1983-11-09	Beecham Group Plc	Chromanols
ES8503669A1 (es) *	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
GB8308064D0 (en) *	1983-03-24	1983-05-05	Beecham Group Plc	Active compounds
FR2546166B1 (fr) *	1983-05-19	1985-10-25	Synthelabo	Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
FR2581993B1 (fr) *	1985-05-14	1988-03-18	Synthelabo	Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) *	1986-06-26	1990-09-18	Ciba-Geigy Corporation	Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) *	1988-02-19	1990-11-06	Eli Lilly And Company	Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) *	1988-07-12	1992-07-10	Synthelabo	Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) *	1989-02-07	1990-11-06	Transitions Research Corporation	Dual bumper-light curtain obstacle detection sensor
US4902695A (en) *	1989-02-13	1990-02-20	Eli Lilly And Company	Excitatory amino acid receptor antagonists
WO1990014087A1 (fr) *	1989-05-17	1990-11-29	Pfizer Inc.	Derives de 2-piperidino-1-alcanol en tant qu'agents antiischemiques
RU2099339C1 (ru) *	1990-02-06	1997-12-20	Пфайзер Инк.	Производные пиперидина
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-11-21 EP EP94931668A patent/EP0741724B1/fr not_active Expired - Lifetime
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 CA CA002182101A patent/CA2182101C/fr not_active Expired - Fee Related
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/fr not_active Ceased
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown

Also Published As

Publication number	Publication date
HU9602100D0 (en)	1996-09-30
NZ275151A (en)	1998-02-26
US5744483A (en)	1998-04-28
FI950403A0 (fi)	1995-01-30
IL112415A0 (en)	1995-03-30
DE69420053D1 (de)	1999-09-16
FI113769B (fi)	2004-06-15
RU2126404C1 (ru)	1999-02-20
CN1048247C (zh)	2000-01-12
CZ286757B6 (en)	2000-06-14
CA2182101A1 (fr)	1995-08-03
NO963186D0 (no)	1996-07-30
DK0741724T3 (da)	1999-12-20
ATE183184T1 (de)	1999-08-15
JP2866743B2 (ja)	1999-03-08
ES2134361T3 (es)	1999-10-01
PE43795A1 (es)	1995-12-09
CO4230161A1 (es)	1995-10-19
AU8066394A (en)	1995-08-15
MY111623A (en)	2000-09-27
EP0741724A1 (fr)	1996-11-13
ZA95692B (en)	1996-07-30
EP0741724B1 (fr)	1999-08-11
CN1142825A (zh)	1997-02-12
IL112415A (en)	1999-07-14
AU684568B2 (en)	1997-12-18
NO963186L (no)	1996-07-30
HU221633B1 (hu)	2002-12-28
CZ225696A3 (en)	1997-01-15
CA2182101C (fr)	1999-08-03
DE69420053T2 (de)	1999-11-25
GR3031356T3 (en)	2000-01-31
PL179448B1 (pl)	2000-09-29
TW449591B (en)	2001-08-11
HUT75942A (en)	1997-05-28
PL315681A1 (en)	1996-11-25
FI950403L (fi)	1995-08-01
WO1995020587A1 (fr)	1995-08-03
JPH09501698A (ja)	1997-02-18
NO309190B1 (no)	2000-12-27
BR9500380A (pt)	1995-10-17
BR9408506A (pt)	1997-08-05

Publication	Publication Date	Title
ZA95692B (en)	1996-07-30	Neuroprotective compounds
UA49869C2 (uk)	2002-10-15	Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
IL114683A0 (en)	1995-11-27	Combination treatment for inhibiting bone loss
ZA953537B (en)	1995-11-06	Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
IL127044A0 (en)	1999-09-22	Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
RU94044489A (ru)	1996-10-20	Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
IL112288A0 (en)	1995-03-30	Application of riluzole in the treatment of mitochondrial diseases
NZ268110A (en)	1999-06-29	Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
EP0653936A1 (fr)	1995-05-24	Utilisation de la 2-(4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinone dans le traitement du cancer.
NZ268914A (en)	1999-06-29	Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
RU94044487A (ru)	1996-10-20	Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
BG105289A (en)	2001-11-30	The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders
AU2796695A (en)	1996-01-15	Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders